SinoInsight 1 March 5 Peruvian media (via Radio Free Asia) reported that Peru’s phase III clinical trials of Sinopharm’s COVID-19 vaccines that were developed by its Wuhan Institute of Biological Products lab and the Beijing Institute of Biological Products lab yielded efficacy rates of 33 percent and 11.5 percent, respectively. This means that …
To access this post, please log in.